COMPANY
Karyopharm Therapeutics Inc.
FDA-approved therapeutic company Clinical Phase 3
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Medical Science Liaison (MSL) - Southwest | US | US-CA | Not stated | Oct 16, 2026 |
| Hematology/Oncology Specialist - Orlando, FL | US-Remote | Not stated | Oct 16, 2026 |
| Karyopharm Talent Community | US-Remote | US-MA-Newton | Not stated | Oct 16, 2026 |
Timeline
- FDA FDA New indication / efficacy supplement: XPOVIO (selinexor) — NDA212306/18, Apr 23, 2026. Applicant at approval: Karyopharm Therapeutics, Inc. Accelerated approval. source ↗
- Raise Private placement: $30M (total, as published), announced Mar 24, 2026. Source: SEC filing. source ↗
- Raise Private placement: $44M (total, as published), announced Oct 8, 2025. Source: SEC filing. source ↗
- Trial start Phase 2: A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia source ↗
- Trial start Phase 3: Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma source ↗
- Trial start Phase 2: A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations source ↗
- Trial start Phase 2: Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma source ↗
- Trial start Phase 2: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis source ↗
- Trial start Phase 3: Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis source ↗
- Trial start Phase 1/Phase 2: Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) source ↗
- Trial start Phase 2/Phase 3: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma source ↗
- Trial start Phase 2: A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. source ↗
- Trial start Phase 1/Phase 2: A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma source ↗
- Trial start Phase 2: Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 source ↗
- Trial start Phase 2: Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection source ↗
- Trial start Phase 1/Phase 2: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of source ↗
- Trial start Phase 3: Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] source ↗
- Trial start Phase 3: Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma source ↗
- Trial start Phase 1: PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) source ↗
- Trial start Phase 2/Phase 3: Selinexor in Advanced Liposarcoma source ↗
- Trial start Phase 1/Phase 2: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications source ↗
- Trial start Phase 2: Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma source ↗
- Trial start Phase 2: Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients source ↗
- Trial start Phase 1/Phase 2: Selinexor and Backbone Treatments of Multiple Myeloma Patients source ↗
- Trial start Phase 1/Phase 2: Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients source ↗
Upcoming milestones
- 2026-12 (ESTIMATED) · Phase 2/Phase 3 · A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · NCT04442022
- 2026-12 (ESTIMATED) · Phase 2 · Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · NCT02227251
- 2027-04 (ESTIMATED) · Phase 1/Phase 2 · Selinexor and Backbone Treatments of Multiple Myeloma Patients · NCT02343042
- 2027-06 (ESTIMATED) · Phase 2 · A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia · NCT05980806
- 2028-01 (ESTIMATED) · Phase 2 · A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. · NCT04414475
Funding
Clinical trials (lead sponsor) 37
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT04256707 | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment | Phase 1/Phase 2 | Completed | Feb 9, 2020 | Jul 31, 2024 (actual) |
| NCT04442022 | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2/Phase 3 | Active, not recruiting | Sep 3, 2020 | 2026-12 (estimated) |
| NCT04414475 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | Phase 2 | Recruiting | Jul 1, 2020 | 2028-01 (estimated) |
| NCT02227251 | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Active, not recruiting | 2014-11 | 2026-12 (estimated) |
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | Phase 3 | Active, not recruiting | Mar 11, 2021 | Feb 20, 2026 (actual) |
| NCT05611931 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Phase 3 | Active, not recruiting | Apr 18, 2023 | May 22, 2026 (actual) |
| NCT02343042 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | Phase 1/Phase 2 | Recruiting | 2015-10 | 2027-04 (estimated) |
| NCT04562870 | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis | Phase 2 | Active, not recruiting | Mar 17, 2021 | 2026-09 (estimated) |
| NCT03555422 | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] | Phase 3 | Completed | Jan 5, 2018 | Jan 22, 2022 (actual) |
| NCT07215832 | Karyopharm Expanded Access Program for Selinexor | Not listed | Available | Not listed | Not listed |
| NCT05980806 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | Phase 2 | Recruiting | Apr 22, 2024 | 2027-06 (estimated) |
| NCT04607772 | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1/Phase 2 | Withdrawn | Nov 18, 2020 | 2025-12 (estimated) |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | Phase 1/Phase 2 | Completed | 2016-01 | Aug 31, 2024 (actual) |
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | Phase 1/Phase 2 | Terminated | Jun 8, 2020 | Jul 3, 2023 (actual) |
| NCT02702492 | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) | Phase 1 | Terminated | Jun 8, 2016 | Jan 26, 2021 (actual) |
| NCT04768881 | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | Phase 2 | Terminated | May 12, 2021 | Sep 22, 2023 (actual) |
| NCT03110562 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | Phase 3 | Completed | May 24, 2017 | Feb 18, 2020 (actual) |
| NCT01896505 | A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma | I | Completed | Jul 30, 2013 | Oct 21, 2016 (actual) |
| NCT04854434 | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations | Phase 2 | Terminated | Jun 29, 2021 | Jun 24, 2022 (actual) |
| NCT02213133 | Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas | Phase 2 | Terminated | Sep 22, 2014 | Dec 10, 2015 (actual) |
| NCT02146833 | SHIP (Selinexor in Hormone Insensitive Prostate Cancer) | Phase 2 | Terminated | 2014-05 | Apr 1, 2016 (actual) |
| NCT02088541 | Selinexor (KPT-330) in Older Patients With Relapsed AML | Phase 2 | Completed | 2014-03 | Jan 8, 2018 (actual) |
| NCT02138786 | Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation | Phase 2 | Terminated | Nov 14, 2014 | Aug 31, 2016 (actual) |
| NCT02389543 | Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients | Phase 1/Phase 2 | Withdrawn | 2015-07 | 2018-01 (estimated) |
| NCT02431351 | Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients | Phase 2 | Withdrawn | 2015-11 | 2017-12 (estimated) |
| NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma | Phase 2 | Withdrawn | 2015-12 | 2017-06 (estimated) |
| NCT02314247 | Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma | Phase 2 | Terminated | 2015-02 | 2016-01 (actual) |
| NCT01607905 | Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer | Phase 1 | Completed | Jun 18, 2012 | Mar 15, 2016 (actual) |
| NCT01986348 | Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas | Phase 2 | Terminated | Mar 3, 2014 | Jan 23, 2020 (actual) |
| NCT02336815 | Selinexor Treatment of Refractory Myeloma | Phase 2 | Completed | May 26, 2015 | Jul 26, 2019 (actual) |
| NCT01607892 | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer | Phase 1 | Completed | Jul 23, 2012 | Oct 13, 2015 (actual) |
| NCT02025985 | Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies | Phase 2 | Completed | Apr 9, 2014 | Jan 24, 2017 (actual) |
| NCT02606461 | Selinexor in Advanced Liposarcoma | Phase 2/Phase 3 | Completed | Jan 4, 2016 | Oct 28, 2020 (actual) |
| NCT04355676 | Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 | Phase 2 | Withdrawn | Apr 30, 2020 | Aug 30, 2020 (actual) |
| NCT02431364 | Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults | Phase 1 | Terminated | May 26, 2015 | Oct 1, 2015 (actual) |
| NCT02367690 | Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients | Phase 1/Phase 2 | Withdrawn | 2015-01 | 2015-05 (actual) |
| NCT04349098 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | Phase 2 | Completed | Apr 17, 2020 | Oct 5, 2020 (actual) |
FDA records (last 2 years)
- FDA New indication / efficacy supplement: XPOVIO (selinexor) — NDA212306/18, Apr 23, 2026. Applicant at approval: Karyopharm Therapeutics, Inc. Accelerated approval. source ↗
Open jobs 3
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Medical Science Liaison (MSL) - Southwest | US | US-CA | Not stated | Oct 16, 2026 | Mid |
| Hematology/Oncology Specialist - Orlando, FL | US-Remote | Not stated | Oct 16, 2026 | Mid |
| Karyopharm Talent Community | US-Remote | US-MA-Newton | Not stated | Oct 16, 2026 | Not stated |
Connect
See your connections at Karyopharm Therapeutics on LinkedIn (search by name, results not checked)